JP2025163108A5 - - Google Patents

Info

Publication number
JP2025163108A5
JP2025163108A5 JP2025127141A JP2025127141A JP2025163108A5 JP 2025163108 A5 JP2025163108 A5 JP 2025163108A5 JP 2025127141 A JP2025127141 A JP 2025127141A JP 2025127141 A JP2025127141 A JP 2025127141A JP 2025163108 A5 JP2025163108 A5 JP 2025163108A5
Authority
JP
Japan
Prior art keywords
formulation
stable liquid
aqueous pharmaceutical
liquid aqueous
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025127141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025163108A (ja
Filing date
Publication date
Priority claimed from JP2022515471A external-priority patent/JP2022547162A/ja
Application filed filed Critical
Publication of JP2025163108A publication Critical patent/JP2025163108A/ja
Publication of JP2025163108A5 publication Critical patent/JP2025163108A5/ja
Pending legal-status Critical Current

Links

JP2025127141A 2019-09-09 2025-07-30 抗IL-23p19抗体製剤 Pending JP2025163108A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962897930P 2019-09-09 2019-09-09
US62/897,930 2019-09-09
JP2022515471A JP2022547162A (ja) 2019-09-09 2020-09-09 抗IL-23p19抗体製剤
PCT/IB2020/058347 WO2021048743A1 (en) 2019-09-09 2020-09-09 Anti-il-23p19 antibody formulations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022515471A Division JP2022547162A (ja) 2019-09-09 2020-09-09 抗IL-23p19抗体製剤

Publications (2)

Publication Number Publication Date
JP2025163108A JP2025163108A (ja) 2025-10-28
JP2025163108A5 true JP2025163108A5 (cg-RX-API-DMAC7.html) 2025-12-15

Family

ID=72615913

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022515471A Pending JP2022547162A (ja) 2019-09-09 2020-09-09 抗IL-23p19抗体製剤
JP2025127141A Pending JP2025163108A (ja) 2019-09-09 2025-07-30 抗IL-23p19抗体製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022515471A Pending JP2022547162A (ja) 2019-09-09 2020-09-09 抗IL-23p19抗体製剤

Country Status (14)

Country Link
US (3) US12577297B2 (cg-RX-API-DMAC7.html)
EP (1) EP4028419A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022547162A (cg-RX-API-DMAC7.html)
KR (1) KR20220062359A (cg-RX-API-DMAC7.html)
CN (4) CN122140915A (cg-RX-API-DMAC7.html)
AU (1) AU2020345071A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022003169A2 (cg-RX-API-DMAC7.html)
CA (1) CA3147328A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002086A1 (cg-RX-API-DMAC7.html)
IL (1) IL291131A (cg-RX-API-DMAC7.html)
MX (1) MX2022002850A (cg-RX-API-DMAC7.html)
PH (1) PH12022550558A1 (cg-RX-API-DMAC7.html)
TW (2) TW202535466A (cg-RX-API-DMAC7.html)
WO (1) WO2021048743A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170120616A (ko) 2015-02-04 2017-10-31 베링거 인겔하임 인터내셔날 게엠베하 염증성 질환의 치료 방법
CA3164996A1 (en) 2019-12-20 2021-06-14 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
WO2023019556A1 (zh) * 2021-08-20 2023-02-23 齐鲁制药有限公司 一种高浓度抗her2的抗体制剂及其用途
WO2023244746A1 (en) * 2022-06-15 2023-12-21 Abbvie Inc. Risankizumab compositions
JP2025535439A (ja) 2022-10-21 2025-10-24 チョン クン ダン ファーマシューティカル コーポレーション 安定した抗体組成物
KR20260094738A (ko) * 2023-09-27 2026-06-23 삼성바이오에피스 주식회사 항-il-23 항체의 안정한 액상 제형
ES3075526A2 (es) * 2023-12-20 2026-08-05 Abbvie Inc Formulaciones de risankizumab de alta concentración
AU2025218720A1 (en) 2024-02-06 2026-05-21 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
WO2025171006A1 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 binding protein compositions and methods of use

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2140933A1 (en) 1992-08-21 1994-02-22 Paula M. Jardieu Method for treating an lfa-1 mediated disorder
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
JP2000510813A (ja) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Il−12用処方
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
ZA986596B (en) 1997-07-25 1999-02-08 Schering Corp Mammalian cytokine related reagents
AU2661199A (en) 1998-02-06 1999-08-23 Schering Corporation Mammalian receptor proteins; related reagents and methods
ATE474849T1 (de) 1998-04-14 2010-08-15 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
DE60038304T3 (de) 1999-09-09 2017-04-06 Merck Sharp & Dohme Corp. Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
US6756481B2 (en) 2000-05-10 2004-06-29 Schering Corporation IL-23 receptor binding compositions
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
US20140186361A1 (en) 2012-09-07 2014-07-03 Coherus Biosciences, Inc. Stable Aqueous Formulations of Adalimumab
JPWO2003034818A1 (ja) 2001-10-24 2005-02-10 中外製薬株式会社 Sgrf遺伝子改変非ヒト動物
US20030138417A1 (en) 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
NZ539271A (en) 2002-10-30 2008-12-24 Genentech Inc Inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23)
AU2003303384A1 (en) 2002-12-23 2004-07-22 Schering Corporation Uses of mammalian cytokine; related reagents
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
ATE440864T1 (de) 2003-03-10 2009-09-15 Schering Corp Verwendung von il-23-antagonisten; verwandte reagenzien
US7413894B2 (en) 2003-07-01 2008-08-19 University Of Virginia Patent Foundation TAG-1 and TAG-2 proteins and uses thereof
PT1684805E (pt) 2003-11-04 2010-10-26 Novartis Vaccines & Diagnostic Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento do mieloma múltiplo
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
AU2004287879C1 (en) 2003-11-04 2011-05-26 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-CD40 monoclonal antibodies and methods for their use
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
CN1942201B (zh) 2004-02-17 2012-06-20 先灵公司 调节il-23活性的方法;相关试剂
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
AU2005241020B2 (en) 2004-05-03 2008-07-10 Merck Sharp & Dohme Corp. Use of IL-17 expression to predict skin inflammation; methods of treatment
EP1799700A4 (en) 2004-09-27 2009-02-11 Centocor Inc SRAGE MIMETIC BODIES, COMPOSITIONS, PROCESSES AND USES
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1853707A2 (en) 2004-12-20 2007-11-14 Schering Corporation Uses of il-23 antagonists in the treatment of diabetes mellitus
AU2006265898A1 (en) 2005-06-30 2007-01-11 Archemix Corp. Polynucleotides and polypeptides of the IL-12 family of cytokines
CA2613818C (en) 2005-06-30 2013-08-27 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
SI1937721T1 (sl) 2005-08-25 2010-11-30 Lilly Co Eli Anti il protitelesa
ME02705B (me) 2005-08-31 2017-10-20 Merck Sharp & Dohme Inženjerisana anti-il-23 antitela
DE602006009834D1 (de) 2005-09-01 2009-11-26 Schering Corp Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
CN101389769A (zh) 2005-12-28 2009-03-18 森托科尔公司 用于评价和治疗银屑病及相关疾病的标记与方法
SI3219328T1 (sl) 2005-12-29 2020-10-30 Janssen Biotech, Inc. Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US20080311043A1 (en) 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス, インコーポレイテッド Il−17およびil−23アンタゴニストならびにその使用方法
CN101472611A (zh) 2006-06-19 2009-07-01 惠氏公司 调节il-22和il-17的方法
CN101600456A (zh) 2006-12-11 2009-12-09 惠氏公司 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物
JP5419709B2 (ja) 2007-01-09 2014-02-19 ワイス・エルエルシー 抗il−13抗体製剤およびその使用
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Il-23拮抗劑於治療感染之用途
US20080200591A1 (en) 2007-02-15 2008-08-21 Isao Noda Melt Processable Reactive Pellets Capable of Forming Ester Condensates and Process for Forming Melt Processable Reactive Pellets
AU2008216090A1 (en) 2007-02-16 2008-08-21 Wyeth Protein formulations containing sorbitol
HUE042172T2 (hu) 2007-02-23 2019-06-28 Merck Sharp & Dohme Genetikailag elõállított anti-il-23P19 antitestek
CN103396489A (zh) 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
MX2009009167A (es) 2007-02-28 2009-09-04 Schering Corp Terapia de combinacion para el tratamiento de trastornos inmunes.
US20090068195A1 (en) 2007-04-23 2009-03-12 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
DK2197903T3 (en) 2007-09-04 2015-01-05 Us Gov Health & Human Serv Deletions in Domain II from Pseudomonas exotoxin A that reduce non-specific TOXICITY
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
WO2009053493A1 (en) 2007-10-26 2009-04-30 Galderma Research & Development Non-invasive method to perform skin inflammatory disease pharmaco-genomic studies and diagnosis method thereof
CA2607771A1 (en) 2007-11-01 2009-05-01 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Humanized anti-venezuelan equine encephalitis virus recombinant antibody
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
MX2011001409A (es) 2008-08-14 2011-03-29 Cephalon Australia Pty Ltd Anticuerpos anti-il-12/il-23.
WO2010027766A1 (en) 2008-08-27 2010-03-11 Schering Corporation Lyophilized formulatons of engineered anti-il-23p19 antibodies
EP2352762A1 (en) 2008-11-03 2011-08-10 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
MX2011005672A (es) 2008-11-28 2011-06-20 Abbott Lab Composiciones de anticuerpo estables y metodos para estabilizar a las mismas.
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2010115786A1 (en) 2009-04-01 2010-10-14 Glaxo Group Limited Anti-il-23 immunoglobulins
EP2414546A4 (en) 2009-04-02 2013-03-13 Univ Johns Hopkins COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASE AND COLON CARCINOMA
US20120269765A1 (en) 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EP2504032A4 (en) 2009-11-24 2013-06-19 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR PREVENTING OR TREATING THROMBOSIS
WO2011069000A2 (en) 2009-12-02 2011-06-09 Spartek Medical, Inc. Low profile spinal prosthesis incorporating a bone anchor having a deflectable post and a compound spinal rod
GB201013975D0 (en) 2010-08-20 2010-10-06 Imp Innovations Ltd Method of treating desease
PE20130041A1 (es) 2010-02-18 2013-01-28 Bristol Myers Squibb Co Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23)
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
SG184355A1 (en) 2010-03-01 2012-11-29 Progenics Pharm Inc Concentrated protein formulations and uses thereof
JP2013531499A (ja) 2010-06-15 2013-08-08 セルジーン コーポレイション 乾癬の治療のためのバイオマーカー
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
JP5972871B2 (ja) 2010-07-20 2016-08-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗il−23ヘテロ二量体特異的抗体
CN103261222B (zh) 2010-09-10 2017-07-28 医疗免疫有限公司 抗体衍生物
KR102049223B1 (ko) 2010-11-04 2019-11-28 베링거 인겔하임 인터내셔날 게엠베하 항-il-23 항체
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
TW201309330A (zh) 2011-01-28 2013-03-01 Abbott Lab 包含糖基化抗體之組合物及其用途
WO2012104402A1 (en) 2011-02-04 2012-08-09 Ab Science Treatment of severe persitent asthma with masitinib
CN109206516A (zh) 2012-05-03 2019-01-15 勃林格殷格翰国际有限公司 抗IL-23p19抗体
EP2863951A1 (en) 2012-06-12 2015-04-29 Boehringer Ingelheim International GmbH Pharmaceutical formulation for a therapeutic antibody
US9803010B2 (en) 2012-06-27 2017-10-31 Merck Sharp & Dohme Corp. Crystalline anti-human IL-23p19 antibodies
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
EP3689369A1 (en) 2013-03-15 2020-08-05 Amgen, Inc Methods for treating psoriasis using an anti-il-23 antibody
US20160031983A1 (en) 2013-03-15 2016-02-04 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
EP3172339A1 (en) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
CA2959629C (en) 2014-09-03 2023-10-31 Boehringer Ingelheim International Gmbh Compound targeting il-23a and tnf-alpha and uses thereof
KR20170120616A (ko) 2015-02-04 2017-10-31 베링거 인겔하임 인터내셔날 게엠베하 염증성 질환의 치료 방법
MX2017013156A (es) 2015-04-14 2018-02-21 Boehringer Ingelheim Int Metodos para tratar enfermedades.
PE20180774A1 (es) 2015-07-23 2018-05-07 Boehringer Ingelheim Int Compuesto que se dirige a il-23a y al factor de activacion de linfocitos b (baff) y usos de estos
TWI811716B (zh) 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
DK3386541T3 (da) 2015-12-07 2020-09-28 Merck Patent Gmbh Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab
AU2017250583A1 (en) 2016-04-15 2018-08-16 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
GB201612317D0 (en) * 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
CA3031860A1 (en) 2016-08-17 2018-02-22 Boehringer Ingelheim International Gmbh Process for the preparation of highly concentrated liquid formulations containing biomolecules
WO2018071504A2 (en) 2016-10-14 2018-04-19 Boehringer Ingelheim International Gmbh Methods of treating diseases
WO2019246271A1 (en) * 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
JP2025535439A (ja) 2022-10-21 2025-10-24 チョン クン ダン ファーマシューティカル コーポレーション 安定した抗体組成物

Similar Documents

Publication Publication Date Title
JP2021155453A5 (cg-RX-API-DMAC7.html)
JP2024001364A5 (cg-RX-API-DMAC7.html)
RU2011140498A (ru) Препарат антител
JP2024160287A5 (cg-RX-API-DMAC7.html)
JP2022166006A5 (cg-RX-API-DMAC7.html)
JP2019534863A5 (cg-RX-API-DMAC7.html)
MX2014013998A (es) Composiciones antimucosidad a base de xilitol y metodos y composiciones.
JP2024156754A5 (cg-RX-API-DMAC7.html)
RU2010119165A (ru) Кортикостероидные композиции
JP2005508981A5 (cg-RX-API-DMAC7.html)
HRP20250278T1 (hr) Puferovane formulacije eksendina (9-39)
RU2574018C2 (ru) Легко дозируемый твердый препарат
BRPI0714224A2 (pt) suspensÕes farmacÊuticas compreendendo fenilefrina e mÉtodos de preparaÇço
CN103260616B (zh) 对乙酰氨基酚的稳定化剂
CN109044981A (zh) 一种普瑞巴林胃漂浮型缓释片及其制备方法
JP2023116498A5 (cg-RX-API-DMAC7.html)
JP2006316075A5 (cg-RX-API-DMAC7.html)
Leonards et al. Aspirin‐induced occult gastrointestinal blood loss: Local versus systemic effects
WO2016163403A1 (ja) 経口フィルム製剤
JP7190538B2 (ja) 医薬組成物
CN102630162B (zh) 4-甲基吡唑制剂
RU2008151945A (ru) Лекарственные формы с пульсирующим высвобождением и фармацевтические композиции фенилэфрина
ME02422B (me) Farmaceutska kompozicija koja uključuje selenit ili uključuje jedinjenja selenita za tretman displazije ili karcinoma cerviksa
CN101405004A (zh) 新型薄膜衣片剂
JP2026016480A5 (cg-RX-API-DMAC7.html)